INTRODUCTION
In recent decades DNA-based materials have revolutionized the scope and complexity of nanomaterials that can be produced. Exploiting the specificity of Watson-Crick base pairing has produced complex dynamic structures such as molecular computers,(1) motors,(2) nanoreactors,(3) as well as sensors and diagnostics. (4) (5) (6) (7) (8) (9) (10) More recently, the ability of certain drugs to intercalate within the DNA double helix and form strong physical complexes has been utilized to form physical prodrugs for cytotoxics. Farokhzad et al. first demonstrated that a DNA aptamer could be loaded with doxorubicin (DOX), allowing targeted uptake into cells presenting the aptamer target. (11) This was extended to aptamer-targeted quantum dots (12) and polymer particles (13) by annealing 4 strands, can be used to deliver DOX to cells, overcoming resistance in a multi-drug CCT CGC TCT GCT AAT CCT GTT A). Conjugates were purified by semi-preparative HPLC with typical isolated yields of 50-80% independent of mPEG length. HPLC and PAGE analysis ( Fig. 2A and   S1 ) confirmed no residual unmodified oligonucleotides in any of the conjugate samples. Molecular masses from MALDI-ToF mass spectrometry were generally in good agreement with theoretical values, however slight deviation from theoretical values was observed. This is not unexpected as mPEG is a disperse polymer and some molecular weight enrichment is likely to occur during HPLC purification i.e. polymer fractionation.
Lyophilized conjugates were dissolved in DNase-free annealing buffer and hybridized with the appropriate complementary strands (e.g. PEG550-A and PEG550-B) to form dsDNA conjugates with mPEG chains at both 5′-termini. Consequently, a series of three PEG DNA conjugates was produced, DNA-PEG550, DNA-PEG1900 and DNA-PEG5K, as well the unPEGylated, "unmodified" DNA.
After annealing, the conjugates were analyzed by PAGE to ensure that no single stranded ODNs were remaining after the annealing ( Fig. 2A and Fig S1A) . PAGE analysis revealed that the PEG-ODNs had successfully formed the double stranded structures. Weak high molecular weight bands were observed for the single strands in all of the gels which arose from self-association of the unhybridized strands under the non-denaturing conditions.
Stability of DNA-PEG conjugates.
To determine the effect of PEG on DNA stability towards nucleases, DNA-PEG conjugates and unmodified DNA were incubated in presence of fetal calf serum. The conditions were chosen to mimic as closely as possible those used for later in vitro experiments to ensure that any effects that arose from differential degradation could be accounted for. The samples were analyzed by native PAGE and individual band intensity estimated using image analysis software. The band intensity of each conjugate at the start of the experiment (0 hours) was set as 100%. All DNA-PEG conjugates were stable for the duration of the experiment with 80-90% remaining after 72 h. Conversely, the unmodified DNA had completely degraded after 72 h and was reduced to approximately 40% after 48 h ( Fig. 2B and S2 ). The conjugation of the PEG polymers to each terminus of the DNA therefore improved its stability significantly and provided protection against the nucleases. However, no effect of polymer molecular weight on stability was observed under these conditions. 
Doxorubicin-loading and affinity
The affinity of doxorubicin (DOX) to the DNA carriers was examined in order to determine the binding of the drug and if this was affected by PEGylation. Doxorubicin binds preferentially to 5′-GC-3′ and 5′-CG-3′ double stranded sequences,(24) thus it is expected that the sequence used here would have two preferential binding sites. Affinity measurements were performed by a previously established fluorescence quenching protocol.(11) The fluorescence of doxorubicin was plotted as a function of the oligonucleotide concentration to produce a Hill plot from which dissociation constants (K d ) were calculated ( Fig. 2C and S3) . Comparison of the calculated K d values showed no difference beyond experimental error between the PEGylated and non-PEGylated DNA, with all being 200 ± 60 nM.
In vitro cytotoxicity studies of DNA-PEG and DOX@DNA-PEG conjugates DNA conjugates promote cell proliferation: To determine if the DNA-PEG conjugates were capable of delivering DOX they were assessed in vitro in A549 cells (lung adenocarcinoma epithelial cells). Carriers were loaded at a 1/10 (w/w) with DOX based on their oligonucleotide content (i.e. 1 mg DOX per 10 mg of ODN) forming the DOX@DNA-PEG conjugates. Cells were incubated with free DOX, DOX@DNA-PEG and empty DNA-PEG carriers for 72 h. DOX concentrations ranged from 0.15 nM-10 μM and were maintained across groups. For the unloaded conjugates the concentrations were matched to the oligonucleotide concentrations used in the DOX@DNA-PEG group. Metabolic activity was assessed by MTT assay, untreated cells were normalized as 100% metabolic activity.
As expected, free DOX resulted in complete suppression of metabolic activity at higher concentrations (≳1 μM), with a calculated IC50 of 89 nM (95% CI 57-131 nM, Fig. 3A) . However, for DOX@DNA-PEG conjugates complete suppression was not seen even at very high concentrations of DOX (10 μM), with approximately 30% metabolic activity remaining compared to untreated cells ( Fig.   3B and S3 ). Although intercalation of the DOX within a carrier is expected to affect cell entry, and thus cytotoxicity, this should be compensated for at the higher concentrations. When considered with the effect of the unloaded DNA-PEG (Fig. 3C ) it is clear that the carriers alone promote metabolic activity/cell growth, and this promotion is also dose dependent. Visual inspection during the course of the experiment revealed that the cell density increased as a function of DNA concentration which was in an agreement with the MTT results. It has previously been shown that pyrimidine nucleosides are growth promoting when they are present in media at a concentration of 1µg/mL with endothelial cells. (Fig. S4 ). For free DOX complete suppression of metabolic activity was observed at high concentrations as before (Fig 4) . However, the calculated IC50 value increased to 124 nM (95% CI 102-151 nM) indicating that a higher dose of DOX is required to inhibit cell growth in the presence of nucleosides, further supporting our previous conclusions. The half maximal inhibitory concentration (IC50) is derived as the mid-point between the maximum and minimum of the dose response curve. However, since the maximal inhibition response varies between DOX@DNA carriers and to that of the free drug direct IC50 comparison between the groups was difficult. Consequently, IC50 values were also calculated by interpolation of the fitted curve at 50% viability. In the case of free DOX, where the maximum inhibition nears 100%, this has little effect on the calculated IC50 (126 nM c.f. 124 nM) however it provides a more realistic value for the DOX@DNA samples. Values calculated by both methods are contained with Table 1 . a Calculated using the 4-parameter variable slope log(inhibitor) vs response model in Graphpad Prism 6.0. As incomplete inhibition was achieved for some treatments these values are relative to the achieved maximum inhibition. b Calculated by interpolation of the fitted curve at 50% relative metabolic activity. c Viability at maximum DOX concentration.
For non-PEGylated DOX@DNA, an IC50 of 132 nM (95% CI 104-165 nM) is comparable to that of free DOX. This is not unexpected considering that the unshielded DNA is readily degraded in the presence of serum and this is likely to be exacerbated in the presence of cells or if internalized.
However, even at the highest non-PEGylated DOX@DNA concentration (1 μM) cell viability remains at ~20% compared to the untreated control. For the DOX@DNA-PEG samples IC50 values are strongly dependent on the molecular weight of the shielding polymer. DOX@DNA-PEG5K and DOX@DNA-PEG550, with IC50s of 232 nM (95% CI 189-282) and 541 nM (95% CI 411-718) respectively, are approximately 2-and 4-fold less toxic than DOX@DNA. DOX@DNA-PEG1900 maintains an IC50 similar to that of DOX@DNA and free drug with an IC50 of 122 nM (95% CI 98-151). The DOX@DNA-PEG conjugates all exhibited dose saturation at highest DOX@DNA concentrations and inhibition was limited to approximately 70% in comparison to 95% inhibition for the free drug.
In vitro studies were extended to a MCF7 cell line (breast adenocarcinoma epithelial cells) to determine if the limiting toxicity was cell line specific. MCF7 cells were more sensitive to DOX with an IC50 of 27 nM (95% CI 20-37) for free drug and all systems were capable of ~90-95% inhibition at the highest concentrations. The greater sensitivity results in less pronounced effects seen with polymer molecular weight, with little variation between treatments, particularly when the large confidence intervals are considered. Lines are calculated four-parameter logistic fits.
Confocal microscopy analysis of cells treated with DOX@DNA
DOX@DNA systems display cell line dependent localization. To further understand the cytotoxicity data DOX@DNA systems were studied by confocal microscopy in A549 and MCF7 cells.
Cells were incubated with DOX@DNA carriers and free DOX and the localization studied at various time points using the inherent fluorescence of the drug for detection. Due to sensitivity requirements the drug concentration was fixed at 3 μM in all cases. After 3 hours (Fig. 5) , free DOX showed intense staining in the nucleus in both cell lines indicating rapid uptake, while in all DOX@DNA nuclear staining was considerably less intense. DOX@DNA samples contain punctate regions within the cytoplasm and in the perinuclear region; this was particularly pronounced in A549 cells. This demonstrates that dsODN are readily internalized into both A549 and MCF7 cells, albeit at lower levels than free drug, and allow trafficking into the target organelle. By 18 hours (Fig. 6) 
Intracellular localization after 18 hours
In order to investigate the intracellular localization of internalized DOX, cells were incubated for 18 hours with free DOX or DOX@DNA and the lysosomal compartments were counterstained (Fig. 7 and   S6 for non-merged images). In MCF7 cells intense doxorubicin staining was observed in the nucleus for all dsODN and free dox. Furthermore, punctate doxorubicin positive regions co-localized with the lysosomal marker. In contrast, A549 cells showed no detectable nuclear staining at 18 hours, even for free DOX, while retaining cytoplasmic doxorubicin positive lysosomal staining. This contrasts with the findings of the previous experiment (Fig. 6) where some low level signal was still detected in nucleus of A549 cells at 18 hours. However, due to the broad excitation/emission spectra of both doxorubicin and the lysosomal marker, the collection range and signal gain for doxorubicin had to be narrowed to prevent signal bleed through. The co-localization assay (Fig. 7) 
CONCLUSIONS
We have described the synthesis and in vitro biological activity of a series of oligonucleotidebased carriers for doxorubicin. Carriers were synthesized by conjugation of PEG to the 5' termini of ODN and hybridization by Watson-Crick base pairing. As expected, PEGylation was found to enhance stability to serum nucleases compared to an unPEGylated control. DOX was successfully bound to the carriers with high affinity (K d ~200 nM) in all cases.
Initial in vitro assays with A549 cells revealed that the carriers promoted cell growth compared to untreated control, with later experiments requiring supplementation with free nucleosides to enable comparison. Comparisons of the metabolic activity, uptake and localization of DOX@DNA systems in A549 and MCF7 cells demonstrated several differences. In MCF7 cells, metabolic activity and uptake were comparable to that of free DOX. Conversely, in A549 cell line DOX@DNA systems had a lesser effect on metabolic activity than free DOX with no system able to achieve more than 70% inhibition. Uptake studies determined that DOX@DNA systems were taken up to a lower extent than free DOX, and that DOX levels in nuclei reduced with time in A549 cells compared to MCF7 cells Our findings highlight the issues that need to be addressed when designing and evaluating oligonucleotide based drug delivery systems. The vast difference observed between the two cell lines underlines the importance of adopting appropriate in vitro models early on and supplementing tissue culture medium with free nucleosides. Our results suggest that our PEGbased system could be used to treat doxorubicin sensitive cancer cells in instances where adverse drug effects are limiting. The data derived from A549 cell line also accentuates the fact that PEGylated-dsODN system would be not suitable to treat drug resistance cells, in those circumstances amphiphilic polymers and known inhibitors of multidrug resistance protein (MRP) should be considered instead. (28, 29) We are currently evaluating alternative dsODN-derived systems to address this issue of drug resistance.
MATERIALS AND METHODS

Materials
All oligonucleotides (HPLC purified) were purchased from Biomers.net GmbH (Ulm, Germany) and used without further purification. MCF-7 and A549 cell lines were received from CRN NCI-60 cell bank. All other solvents and reagents were of analytical or HPLC grade and purchased from Sigma Aldrich unless otherwise specified.
NMR Spectroscopy
NMR spectra were recorded on a Bruker Avance 400 spectrometer at 400. 
MALDI-ToF Mass Spectrometry
Matrix-assisted laser desorption/ionization time-of flight (MALDI-ToF) mass spectrometry was performed on a Bruker MALDI-ToF Ultra Flex III spectrometer operated in linear, positive ion mode. 3-HPA containing DAHC was used as the matrix for oligonucleotide analysis. Briefly, a saturated solution of 3-HPA (50 mg/mL) was prepared by adding 25 µg of 3-HPA to 500 µL of 50% MeCN/water. 25 µL of DAHC solution (100 mg/mL) was added to 225 µL of the 3-HPA solution, to give a final DAHC concentration of 10 mg/mL. ODN solutions were desalted prior to mixing with matrix using C18 Ziptips. Equal volumes of matrix solution and ODN solution (0.2 mM) were mixed and 2 µL of the mixture was spotted onto the MALDI plate and allowed to dry.
Polyacrylamide Gel Electrophoresis
Polyacrylamide gel electrophoresis (PAGE) analysis was performed at 160 mV using a 15% acrylamide running gel. Native gels were prepared using acrylamide-bis-acrylamide ( 
Hybridization of DNA strands
Strands were hybridized in annealing buffer which consisted of 10 mM Tris, 50 mM NaCl and 1 mM EDTA pH 7.5. For the hybridisation the strands were mixed in equimolar quantities to
give a final concentration of 75 µM of each strand and placed in a water bath at 95 °C for 5 minutes. The water bath was then turned off and allowed to cool slowly to room temperature.
Annealed strands were desalted using a PD SpinTrap G-25 column (GE Healthcare) and oligonucleotide concentration determined by optical density @ 260 nm (1 OD = 30 ug/mL).
Annealing was verified using PAGE gel under non-denaturing conditions. Solutions were aliquoted, lyophilized and stored at -20 °C until needed.
Drug loading of DNA carriers
Doxorubicin HCl (Dox HCl) (1 mg) was dissolved in UHQ water (1 mL). The solution was filtered through a 0.22 µm PES syringe filter and stored at 4 °C until use. DNA carriers were dissolved in sterile DPBS. Dox HCl was added to the DNA solution in order to achieve a 10% Cytotoxicity Assays. Cells were allowed to reach confluence in the T75 flasks before being seeded onto 96-well plates. Cells were seeded at 5×10 3 cells/well for both cell lines (100 µL, 5×10 4 cells/mL). Cells were allowed to attach for 24 hours before the media was removed and replaced with 100 µL of media containing the appropriate DOX concentration. For experiments with carrier alone, an equivalent concentration of DNA (without drug) was used. 6 wells were used for each concentration. Cells were treated for 72 hours before metabolic activity was determined using an MTT assay. MTT solution (10 µL of 5 mg/mL) in media was added to each well and allowed to develop for 75 minutes. The media was then carefully aspirated and wells washed with PBS (100 μL). The formazan crystals were finally dissolved by adding DMSO (100 µL) to each well. The plate was read using a Tecan M200 platereader at 562 nm and the MTT response compared to untreated cells. Untreated cells were normalized as 100% metabolic activity.
Toxicity curves were fitted with Graphpad Prism 6.0 using the 4-parameter variable slope log(inhibitor) vs response model. Due to incomplete inhibition IC50 calculated are considered as relative. Real IC50 values were calculated by interpolation of the fitted curve within the same software.
Confocal Microscopy
Cells were seeded on Nunc LabTekII coverglass 8 well slides at 20,000 cells/well and 
